Drug Interactions between Nuedexta and sofpironium topical

Using dextromethorphan together with quiNIDine may increase the effects of dextromethorphan. Contact your doctor if you experience difficulty breathing, dizziness, drowsiness, anxiety, restless feeling, nervousness, confusion, or diarrhea. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2 -fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose.

MANAGEMENT: Coadministration of topical sofpironium with potent CYP450 2D6 inhibitors should generally be avoided. If coadministration is required, monitor for sofpironium-related adverse effects which include blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.